ProCE Banner Activity

Improving Outcomes in Patients With RVO: Tailoring Treatment

Slideset

This downloadable slide set presents key data about anti-VEGF therapies for RVO, developing treatment protocols that use current therapies most effectively to improve outcomes, and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.

Released: October 03, 2023

Expiration: October 03, 2024

Share

Faculty

Carl J. Danzig

Carl J. Danzig, MD

Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, Florida
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Arshad M. Khanani

Arshad M. Khanani, MD, MA, FASRS

Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, Nevada

Ashleigh Levison

Ashleigh Levison, MD

Partner Physician
Colorado Retina Associates
Denver, Colorado 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Disclosure

Primary Author

Carl J. Danzig, MD

Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, Florida
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Carl J. Danzig, MD: consultant/advisor/speaker: Adverum, Alimera, Genentech, Kodiak Sciences, IvericBio, Regeneron.

Arshad M. Khanani, MD, MA, FASRS

Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, Nevada

Arshad M. Khanani, MD, MA, FASRS:  consultant: 4D Molecular Therapeutics, AbbVie, Adverum, Aerie, Aldebaran, Allergan, Amgen, Annexin, Annexon, Apellis, Applied Genetics Technologies Corporation, Arrowhead, Ashvattha, Aviceda Therapeutics, Bausch & Lomb, Beacon Therapeutics, Broadwing Bio, Clearside, Exgenesis, EyePoint, Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kartos, Kato, Kodiak Sciences, Kriya, Nanoscope, Notal, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olives Bio, Opthea, Oxurion, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Thea, Unity, Vanotech, Vial; researcher: 4D Molecular Therapeutics, Adverum, Alexion, Annexon, Apellis, Exegenesis, Genentech, Inc., Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxular, Oxurion, Regenxbio, Rezolute, Roche, Unity, Vanotech.

Ashleigh Levison, MD

Partner Physician
Colorado Retina Associates
Denver, Colorado 

Ashleigh Levison, MD, has no relevant financial relationships to disclose.